Prabin joined the WorldWide Antimalarial Research Network (WWARN) – the prototypic model to IDDO – as a statistician in September 2011. His work with WWARN included assessment of the relationship between weight-adjusted dose and parasitological outcomes for artemisinin combination therapies.
His doctoral thesis (2015–2018, Linacre College) explored different statistical approaches for handling parasitic recurrences when quantifying antimalarial blood stage efficacy in P. falciparum.
In his current role, Prabin's main focus is the quantification of risk of severe and serious adverse events following antileishmanial therapies. His interest lies in exploring methodological issues in design and analysis of antileishmanial clinical trials.
Research Theme: VL, Malaria, Non-Malarial Febrile Illness